18results about "Hepatocytes" patented technology

To provide a technique for suppressing functional variations between a plurality of neural cell-containing spheroids across a plurality of lots or within a single lot.SOLUTION: The present invention relates to a cell-containing vessel comprising a plurality of neural cell-containing spheroids for which the variation calculated by the calculation method described below is less than 20%, where the neural cell-containing spheroids contain a plurality of types of cells including neural cells. (Calculation Method) Calcium transient assays are conducted for each of a plurality of neural cell-containing spheroids, a number of spontaneous oscillations per 10 minutes is measured, an average and a standard deviation for the number of spontaneous oscillations are calculated, and a variation is calculated by the following formula (1). Variation (%)=standard deviation for number of spontaneous oscillations / average number of spontaneous oscillations×100.SELECTED DRAWING: None

Disclosed are methods of treating or reducing the occurrence of a steatohepatitis disorder. The disorder may include, for example, NASH, parenteral nutrition associated liver disease (PNALD), or genetic forms of liver disease. The method may comprise the step of administering a composition comprising obeticholic acid to an individual in need thereof.

The present disclosure provides a method of performing a functional assay on human spheroids, e.g., three-dimensional human cell spheroids using, in one embodiment, a fluorometric imaging plate reader.

A cell or tissue embedding device highly capable of supplying a physiologically active substance is disclosed. The device includes an aqueous gel that serves as an immunoisolation layer and the aqueous gel includes a polyvinyl alcohol resin with a syndiotacticity of 32 to 40% in triad. A process of preparing a PVA gel containing living cells or living tissue is disclosed and the process provides less reduction of the living cells or living tissue during preparation of the PVA gel.

The invention relates to a liver organoid, uses thereof and method for obtaining them.

The present invention relates to a three-dimensional (3D) co-culture system that mimics the MASLD microenvironment and is used to investigate its effects on hepatocellular carcinoma (HCC). The system comprises hepatic stellate cells embedded in a collagen matrix and HCC cells cultured in a metabolic medium that simulates MASLD conditions. This model enables the investigation of the molecular mechanisms of HCC under laboratory conditions and can be used to identify new therapeutic targets.

To provide methods of making and using lipotoxic organoid models.SOLUTION: A method of making a lipotoxic organoid model comprises the steps of contacting a liver organoid with a free fatty acid (FFA) composition, wherein the FFA composition comprises oleic acid, linoleic acid, palmitic acid, or combinations thereof, preferably oleic acid.SELECTED DRAWING: None

The present disclosure provides an encapsulated liver tissue that can be used in vivo to improve liver functions, in vitro to determine the hepatic metabolism and / or hepatotoxicity of an agent and ex vivo to remove toxic compounds from patients' biological fluid. The encapsulated liver tissue comprises at least one liver organoid at least partially covered with a biocompatible cross-linked polymer. Processes for making the encapsulated liver tissue are also provided.

Provided here are cell culture system with tunable stiffness comprising a biocompatible polydimethyl siloxane substrate and a polyelectrolyte multilayer. Also provided here are methods of making and using these systems as research and / or product development models for different tissue and organ systems.

This invention provides a non-human vertebrate exhibiting a higher human liver cell growth rate, a higher human liver cell replacement rate, and higher histological-physiological human reproducibility than existing non-human vertebrates comprising the human liver transplanted therein and a method for producing such non-human vertebrate. Specifically, the method for producing a transgenic non-human vertebrate comprising human liver cells transplanted therein comprises transplanting human liver cells in a non-human vertebrate that has impaired or lowered immune reactions against humans in the presence of human IL-6 in vivo.

A use of uridine diphosphate glucose (UDPG) in treatment of abnormal liver glucolipid metabolism. Specifically, a use of UDPG or a pharmaceutical composition comprising same in the preparation of a drug for preventing and / or treating abnormal liver glucolipid metabolism, wherein the abnormal liver glucolipid metabolism is preferably nonalcoholic fatty liver disease, dyslipidemia and related cardiovascular diseases. Treatment using UDPG can reduce lipid synthesis and lipid synthesis related gene expression in the liver.

Certain populations of small cells present in adult human tissue can undergo activation / development to form human pluripotent stem cell populations. These small cells are generally less than six micrometers in diameter and are CD49f-positive, and are referred to herein as human early stage precursors or CD49f+ cells. Accordingly, provided are cell populations and compositions with enriched CD49f+ cells from adult human tissue samples and methods and compositions for promoting activation / development of these CD49f+ cells. Upon differentiation, the activated stem cells can be used for various therapeutic purposes.

The present invention relates to a three-dimensional hepatic tissue comprising a cell structure containing at least hepatocytes, and a hydrogel, wherein the cell structure does not contain hepatic stellate cells, and the cell structure is embedded in the hydrogel.

The present invention solves the following problems [1] to [3] found in conventional methods of preparing a three dimensional structure (organ primordium) by coculturing functional cells with umbilical cord-derived vascular endothelial cells and bone marrow-derived mesenchymal cells: [1] the quality of resultant organ primordia varies greatly depending on donors; [2] the growth capacities of cell sources are limited; and [3] it is difficult to secure immunocompatibility because cells are derived from different sources. An organ bud prepared from vascular cells, mesenchymal cells and tissue or organ cells, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells. A method of preparing an organ bud, comprising culturing vascular cells, mesenchymal cells and tissue or organ cells in vitro, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells.

The liquid-tight case includes a housing for enclosing a tissue device, the tissue device having a first channel network and a second channel network in fluid communication with the first channel network. The liquid-tight case also includes a first inlet port, a second inlet port, and at least one outlet port. The first inlet port is formed in or coupled to the housing and configured to be in fluid communication with the first channel network of the tissue device. The second inlet port is formed in or coupled to the housing and configured to be in fluid communication with the second channel network of the tissue device. The at least one outlet port is formed in or coupled to the housing. The liquid-tight case allows the tissue device to have more flexible and more complex designs with more suitable or modified materials for cell migration and tissue formation.

A population of minute dormant cells is isolated from adult tissue that exhibit unique properties after activation and growth in vitro, referred to herein as pilot cells, different from all known cell types. The guided cells can interact with somatic cells to produce a novel high-plasticity stem cell, referred to herein as guided integrated adult stem cells (giaSC). Thus, cell populations and compositions having high plasticity stem cells or guide cells, as well as methods of producing such cell populations and compositions, are provided. Also provided are methods of modulating somatic cells by interacting with guide cells or cellular components thereof. The compositions and methods are useful for a variety of therapeutic purposes.

The present invention provides, inter alia, a method for preparing a liver or pancreas graft, comprising the following steps: 2a) providing a carrier matrix suitable for tissue engineering and a cell suspension comprising viable hepatocytes and / or islet cells in a standard culture medium A; 2b) loading the cell suspension onto the carrier matrix; 2c) incubating the loaded matrix in either -standard culture medium A or -standard culture medium A and culture medium B comprising 0.5%-5% secretome at about 37°C for a first incubation time T1 of at least 10 hours; 2d) replacing the culture medium of step 2c) with a culture medium B comprising standard culture medium A and 0.5%-5% secretome; 2e) incubating the loaded matrix in culture medium B at about 37°C for a second incubation time T2 of at least 24 hours; 2f) washing the loaded matrix of step e) with standard culture medium A to remove at least a portion of the secretome.